PT  - JOURNAL ARTICLE
AU  - Racine-Brzostek, Sabrina E.
AU  - Karbaschi, Mohsen
AU  - Gaebler, Christian
AU  - Klasse, P.J.
AU  - Yee, Jim
AU  - Caskey, Marina
AU  - Yang, He S.
AU  - Hao, Ying
AU  - Chadburn, Amy
AU  - Shi, Yuanyuan
AU  - Zuk, Robert
AU  - Nussenzweig, Michel C.
AU  - Cushing, Melissa M.
AU  - Zhao, Zhen
TI  - TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
AID  - 10.1101/2021.02.03.21251089
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.03.21251089
4099  - http://medrxiv.org/content/early/2021/02/08/2021.02.03.21251089.short
4100  - http://medrxiv.org/content/early/2021/02/08/2021.02.03.21251089.full
AB  - Background There is a concern that low initial SARS-CoV-2 antibody titers in individuals may drop to undetectable levels within months after infection. Although this may raise concerns over long term immunity, both the antibody levels and avidity of the antibody-antigen interaction should be examined to understand the quality of the antibody response.Methods A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 1.3 and 6.2 months post-infection in paired samples from 80 COVID-19 patients.Results The newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay (R=0.88). The imprecision of the TOP avidity assay was less than 9%. Although TAb and neutralization activity (by SNAb) decreased between 1.3 and 6.2 months post infection, the antibody avidity increased significantly (P < 0.0001).Conclusion This highly precise and versatile TOP-Plus panel with the ability to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody levels and avidity of individual sera on one sensor can become a valuable asset in monitoring not only SARS-CoV-2-infected patients, but also the status of individuals’ COVID-19 vaccination response.Competing Interest StatementZ.Z. received seed instruments and sponsored travel from ET Healthcare. Y.H. was funded by China Scholarship Council. The rest of the authors declare that they have no conflict of interests with the present workFunding StatementThis work was supported by a COVID-19 research grant from Weill Cornell Medicine (M.C.), Weill Cornell Medicine Translational Research Program of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine (grant number COVID3376; Z.Z.). NIH grant R01 AI36082 (P.J.K.) and NIH grant P01-AI138398-S1 and 2U19AI111825 (M.C.N.). C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in part by the National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award program, grant UL1 TR001866), and by the Shapiro-Silverberg Fund for the Advancement of Translational Research. M.C.N. is a Howard Hughes Medical Institute Investigators. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Rockefeller University (IRB# DRO-1006) and determined to meet exemption requirements by Weill Cornell Medicine Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAn anonymized dataset and data analysis code may be available upon application to the corresponding author and institutional review as per Weill Cornell Medicine data sharing policiesCOVID-19Corona Virus Disease-2019SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2RT-PCRreal-time polymerase chain reactionRBDreceptor-binding domainTOPtesting-on-a-probeHPLChigh performance liquid chromatographySRIDsingle radial immunodiffusionSPRSurface Plasmon ResonanceBLIBio-Layer InterferometryRFUrelative fluorescence unitdRrelative dissociation rateTAbtotal antibodySNAbsurrogate neutralizing antibodyELISAEnzyme-linked immunosorbent assaysPRNTplaque reduction neutralization testPsVpseudo virus neutralization test